Message to users of the Textise Firefox add-on:
Due to difficulties keeping the add-on compatible with marching versions of Firefox, it is now a legacy tool.
Instead, we recommend you use the Textise bookmarklet.
The bookmarklet is easy to install and easy to use; it's cross-browser compatible and won't go out of date!


This page has been Textised!
The original page address was https://noharm-uscanada.org/issues/us-canada/mercury


Choose a Region
Search
Advanced
Search »
 
Advanced Search
Region
Content Type
Date Range
From:
Date
E.g., 12/10/2017
-
Date
E.g., 12/10/2017
[Image: Homepage]   Text
Only
  Somente
texto
  Solo
texto
 
Make a Donation
Menu
             
You are here
  1. Home
  2. Issues
  3. Mercury
Mercury



The Issue 
Mercury no more
On August 16, 2017, the Minamata Convention on Mercury, a global treaty that will phase out mercury-based medical devices by 2020, entered into force. Read more.

Mercury is a potent neurotoxin that can harm the brain, spinal cord, kidneys, and liver. It is used throughout health care in a variety of products, including thermometers; sphygmomanometers; dental amalgam; laboratory chemicals; preservatives such as thimerosal; cleaning agents; and various electronic devices such as fluorescent lamps and computer equipment.

The cumulative usage, spills, breakages, and disposal of these products makes the health care sector a significant contributor of mercury pollution in the environment. 

Fortunately, it is relatively easy to phase out the use of mercury because of the many safe, cost-effective non-mercury alternatives that exist for nearly all uses of mercury in health care. 

As part of a global initiative to reduce the use and spread of mercury in all aspects of society, Health Care Without Harm is leading the effort to eliminate mercury from the health care sector. 

Issues & Programs
Issues
Issues
Newsletter - US and Canada


Textise: Back to top

This text-only page was created by Textise (www.textise.net). Copyright Subjunctive Software.
Find us on Facebook and Twitter or visit the Official Blog.